From Inc · · 1m 20s
Ferring Acquires Gameto for $1.4 Billion to Improve Fertility Treatments
Ferring Pharmaceuticals buys Gameto for $1.4 billion to make IVF safer and more affordable for women.
In brief
Ferring Pharmaceuticals buys Gameto for $1.4 billion to make IVF safer and more affordable for women. Ferring Pharmaceuticals acquired Gameto for $1.4 billion to improve fertility treatments through Fertilo technology, reducing injections and risks. Originally reported by Inc.
Ferring Acquires Gameto
Ferring Pharmaceuticals has agreed to acquire Austin-based biotech company Gameto for $1.4 billion.
Gameto's Fertilo Technology
Gameto's Fertilo technology matures eggs outside the body, reducing injections from 12 days to three days.
Fertilo Benefits
Fertilo lowers risks for women with health conditions and reduces side effects from hormone doses.
Clinical Trials
Gameto's technology is in phase 3 clinical trials but expected to win regulatory approval.
Dr. Dina Turner's Statement
Dr. Dina Turner, Gameto co-founder and CEO, said combining their cell-engineering platform with Ferring's global reach will accelerate innovation.
Traditional IVF Process
Traditional IVF requires up to two weeks of self-administered injections to produce multiple mature eggs.
Fertilo's Advantages
Fertilo yields healthy eggs ready for fertilization and protects patients from systemic hormonal stimulation.
Fertilo's Effectiveness
Fertilo is less expensive and less risky than traditional IVF but slightly less effective, according to 2020 research.
What Happens Next
Ferring and Gameto aim to expand access to modern fertility treatments globally by 2027.
The short version
Ferring Pharmaceuticals acquired Gameto for $1.4 billion to improve fertility treatments through Fertilo technology, reducing injections and risks.
